Enterprise Value
15.25M
Cash
159.7M
Avg Qtr Burn
-23.43M
Short % of Float
15.66%
Insider Ownership
1.42%
Institutional Own.
68.00%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ADI-001 (allogeneic CAR gamma-delta T cell therapy) Details Non-Hodgkin lymphoma, Cancer, Diffuse large B cell lymphoma | Phase 1 Data readout | |
ADI-270 Details Cancer, Solid tumor/s, Hematologic malignancies | IND Submission |